Coronavirus (848) Weekly update no.15 - Evidence Aid COVID-19 project

22 July, 2020

Dear Friends (with apologies for any cross-posting),

Here is the 15th weekly update on our COVID-19 project.

Highlights: The number of users on the website has now exceeded 150,000. Also this week, all but one of the top ten countries by audience numbers were lower- and -middle income countries (the exception being Chile). Last but not least, we have summarised more than 350 systematic reviews.

Evidence Aid COVID-19 Weekly Bulletin

Report covering 7 days to 21th July 2020 -

Systematic review summaries

356 summaries on the website in total (19 added in this period); 95 summaries in progress;


340 in Arabic; 339 in Chinese (simplified); 340 in Chinese (traditional); 339 in French; 42 in Italian; 339 in Portuguese; 337 in Spanish;

Literature searches

0 search completed in this period; 1 search in progress; 468 records were screened


A total of 64 amazing volunteers (39 summary writers; 10 screeners; 15 information specialists/librarians) from 15 countries;

Digital engagement

20,819 people have used the Evidence website in this 7-day period for a total of 154,446 users since we started collecting data in mid-March. Our top ten countries this week were: Mexico, Egypt, Chile, India, El Salvador, South Africa, Algeria, Iraq and DRC.

The summaries with most views this week were Rehabilitation and early mobilisation in the critical patient (in Spanish) D-dimer levels associated with severity of COVID-19 (in Arabic), and Physical interventions to interrupt or reduce the spread of respiratory viruse (in Spanish).


We are grateful to Twitter, who have granted us substantial pro-bono advertising. Among others, we are collaborating with WHO, Public Health England, PAHO, Queen’s University Belfast, Health and Social Care Northern Ireland, Cochrane, Campbell, Translators Without Borders, Global Evidence Synthesis Initiative, the Irish Global Health Network, Health Service Executive Ireland, McMaster University (COVID-END) and Oxford PharmaGenesis. Evidence Aid are supported by H2H, with funding from UK Aid, and by a core grant from Oxford PharmaGenesis. This week, we were really pleased to present our work to over 80 members of staff from Oxford Pharmagenesis and were able to thank those who have volunteered on our COVID-19 project.

Best wishes,


Ben Heaven Taylor

Chief Executive Officer

Email: | skype: live:ben_taylor45 |Phone: +44 (0)7880 635014 |Web: | Twitter @EvidenceAid

Championing evidence-based humanitarian action

Support our activities by donating here.

For the Evidence Aid resources on COVID-19 (Coronavirus), visit